PHARMACOKINETICS OF PEG-INTERFERON LAMBDA (PEG-IFN-λ) IN A DOSE-RANGING PHASE 1B STUDY IN HEPATITIS C PATIENTS

被引：0
|
作者：
Byrnes-Blake, K. A. [1 ]
Freeman, J. A. [1 ]
Dodds, M. G. [1 ]
Rapalus, L. [1 ]
Pederson, S. [1 ]
Hunder, N. [2 ]
Miller, D. M. [1 ]
机构：
[1] ZymoGenetics Inc, Preclin Dev, Seattle, WA USA
[2] ZymoGenetics Inc, Clin Dev, Seattle, WA USA
来源：
JOURNAL OF HEPATOLOGY | 2010年 / 52卷
关键词：
D O I：
10.1016/S0168-8278(10)60281-4
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S117 / S117
页数：1
相关论文
共 50 条
  • [1] PHARMACOKINETICS OF PEG-INTERFERON LAMBDA (PEG-IFN-λ) FOLLOWING FIXED DOSING IN TREATMENT-NAiVE HEPATITIS C SUBJECTS (SINGLE DOSE INTERIM DATA FROM A DOSE-RANGING PHASE 2A STUDY)
    Byrnes-Blake, Kelly A.
    Freeman, Jeremy A.
    Rapalus, Lisa
    Pederson, Susan
    Fontana, David
    Lopez-Talavera, Juan Carlos
    Kansra, Vikram
    Miller, Dennis M.
    HEPATOLOGY, 2010, 52 (04) : 720A - 721A
  • [2] A PHASE 1B DOSE-RANGING STUDY OF 4 WEEKS OF PEG-INTERFERON (IFN) LAMBDA (PEG-RIL-29) IN COMBINATION WITH RIBAVIRIN (RBV) IN PATIENTS WITH CHRONIC GENOTYPE 1 HEPATITIS C VIRUS (HCV) INFECTION
    Muir, Andrew
    Shiffman, Mitchell L.
    Zaman, Atif
    Yoffe, Boris
    Lopez-Talavera, Juan Carlos
    Souza, Sherri
    Hausman, Diana F.
    Lawitz, Eric
    HEPATOLOGY, 2009, 50 (04) : 1039A - 1040A
  • [3] THE EFFECT OF TREATMENT GROUP, HCV GENOTYPE, AND IL28B GENOTYPE ON EARLY HCV VIRAL KINETICS IN A PHASE 2A STUDY OF PEG-INTERFERON LAMBDA (PEG-IFN-λ) IN HEPATITIS C PATIENTS
    Freeman, Jeremy A.
    Gray, Todd E.
    Fontana, David
    Lopez-Talavera, Juan Carlos
    Miller, Dennis M.
    Hillson, Jan L.
    HEPATOLOGY, 2010, 52 (04) : 721A - 721A
  • [4] PEG-IFN-λ: ANTIVIRAL ACTIVITY AND SAFETY PROFILE IN A 4-WEEK PHASE 1B STUDY IN RELAPSED GENOTYPE 1 HEPATITIS C INFECTION
    Shiffman, M.
    Lawitz, E.
    Zaman, A.
    Vierling, J.
    Yoffe, B.
    Freeman, J.
    Gray, T.
    Hausman, D.
    Muir, A.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S237 - S237
  • [5] Peg-interferon lambda Treatment induces robust innate and adaptive immunity in chronic hepatitis B Patients
    Phillips, Sandra
    Mistry, Sameer
    Riva, Antonio
    Cooksley, Helen
    Hadzhiolova-Lebeau, Tanya
    Plavova, Slava
    Katzarov, Krum
    Simonova, Marieta
    Zeuzem, Stephan
    Woffendin, Clive
    Chen, Pei-Jer
    Peng, Cheng-Yuan
    Chang, Ting-Tsung
    Lueth, Stefan
    De Knegt, Robert
    Choi, Moon-Seok
    Wedemeyer, Heiner
    Dao, Michael
    Kim, Chang-Wook
    Chu, Heng-Chen
    Wind-Rotolo, Megan
    Williams, Roger
    Cooney, Elizabeth
    Chokshi, Shilpa
    FRONTIERS IN IMMUNOLOGY, 2017, 8
  • [6] INTERIM RESULTS FROM A PHASE 1B DOSE-ESCALATION STUDY OF 4 WEEKS OF PEG-INTERFERON LAMBDA (PEG-RIL-29) TREATMENT IN SUBJECTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE 1 WITH PRIOR VIROLOGIC RESPONSE AND RELAPSE TO PEGINTERFERON ALFA AND RIBAVIRIN
    Lawitz, Eric J.
    Zaman, Atif
    Muir, Andrew J.
    Shiffman, Mitchell L.
    Yoffe, Boris
    Zhang, Tracy
    Souza, Sherri
    Hausman, Diana F.
    HEPATOLOGY, 2008, 48 (04) : 385A - 385A
  • [7] PEG-interferon alfa-2b for acute hepatitis C: A review
    Palumbo, Emilio
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2007, 7 (08) : 839 - 843
  • [8] ELIGIBILITY 2: A PROSPECTIVE, OBSERVATIONAL, MULTICENTRE STUDY ON OUTCOMES OF PEG-INTERFERON/RIBAVIRIN (PEG-IFN/RBV) IN CHRONIC HEPATITIS C (CHC)
    Vukotic, R.
    Gamal, N.
    Andreone, P.
    DIGESTIVE AND LIVER DISEASE, 2014, 46 : E45 - E46
  • [9] Treatment with Peg-interferon alfa-2b in patients affected by acute hepatitis C: A pilot study
    Scotto, G
    Palumbo, E
    Fazio, V
    Cibelli, DC
    Saracino, A
    Angarano, G
    HEPATOLOGY, 2004, 40 (04) : 331A - 331A
  • [10] Treatment with PEG-interferon and ribavirin therapy in dialysis patients with chronic hepatitis C
    Tan, Adriaan C.
    de Vries, Richard A.
    Adang, Rob
    Konings, Stijn
    Cnossen, Nynke
    Schalm, Solko W.
    van Leusen, Rob
    HEPATOLOGY, 2006, 44 (04) : 321A - 321A
12345